Cord Blood News 12.18 May 14, 2020 | |
| |
TOP STORYInvestigators established a safety evaluation system for therapeutic stromal cells based on the existing regulations and current testing techniques to provide general quality requirements for human umbilical cord MSC therapy product. [Stem Cell Res Ther] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Scientists demonstrated that cord blood-endothelial progenitor cell-derived endothelial colony forming cells (CB-ECFCs) expressed HLA-G, IL-10, and TGF-β1 and secreted IL-10 and TGF-β1 and that they could display immunosuppressive properties in vitro. CB-ECFCs could be tolerated until 14-days in immunocompetent mice. [Stem Cell Res Ther] Full Article The authors demonstrated that human umbilical cord blood regulatory T cells modulated the central and peripheral immune response after injury in vitro and in vivo. [Stem Cells Transl Med] Full Article Researchers compared MSCs from the umbilical cord blood, dental pulp, and liposuction material on their ability to respond to activated neutrophils. [J Cell Physiol] Abstract Cocultured human umbilical cord MSCs (hUCMSCs) and human umbilical vein endothelial cells (HUVECs) promoted vascular formation of HUVECs, and the optimal coculture ration was 1:5 (hUCMSCs:HUVECs). hUCMSCs promoted angiogenesis of HUVECs through the long noncoding RNA HIF1A-AS2-activation of the Hif-1 signaling pathway. [Life Sci] Abstract Cloning of MSCs was attainable when cultured in mouse embryonic fibroblast conditioned media. Single clones with higher proliferation and differentiation potential than their original progenitor cells were obtained by cloning of poorly functioning MSCs progenitor cells, enabling the selection of more therapeutically efficacious MSCs with better performance in clinical applications. [Mol Biol Rep] Abstract Subscribe to one of our other 19 science newsletters such as Hematopoiesis News & Cell Therapy News. | |
| |
REVIEWSIdentifying the Therapeutic Significance of Mesenchymal Stem Cells Scientists address the immunomodulatory properties and immunosuppressive actions of MSCs. They also sum up the results of the enhancement, utilization, and therapeutic responses of MSCs in treating inflammatory diseases, metabolic disorders and diabetes. [Cells] Full Article Visit our reviews page to see a complete list of reviews in the cord blood research field. | |
| |
INDUSTRY NEWSAscentage Pharma announced that the FDA has granted HQP1351, the company’s core drug candidate, a Fast Track Designation for the treatment of patients with chronic myeloid leukemia with certain genetic mutations who have failed to respond to treatments with existing tyrosine kinase inhibitors. [Ascentage Pharma] Press Release | |
| |
POLICY NEWSScientists Are Drowning in COVID-19 Papers. Can New Tools Keep Them Afloat? Backed by large technology firms and the White House, a loose-knit army of data scientists, software developers, and journal publishers are racing to create digital collections holding thousands of freely available papers that could be useful to ending the pandemic, and scrambling to build data-mining and search tools that can help researchers quickly find the information they seek. [ScienceInsider] Editorial House Democrats Include Research Dollars in Latest Pandemic Relief Package For US scientists, the good news is that the $3 trillion spending bill unveiled contains billions of dollars in new research funding. The bad news is that the bill is only a marker for negotiations with Senate Republicans and the White House on what more the federal government should do to help the country deal with the devastating economic and health effects of the pandemic. [ScienceInsider] Editorial
| |
EVENTSIn light of COVID-19, many conferences are being cancelled or postponed. As such: We are suspending new event postings in our newsletters and on Twitter. Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Fellow – Molecular Hematology (Heidelberg University Hospital) NEW Head – Hematological Cancer (Ichnos) Postdoctoral Position – Tumor Immunology (University of Maryland) Senior Scientist – Cell Engineering (Merck & Co., Inc.) Project Manager – Precision Medicine (Prinses Máxima Centrum) Postdoctoral Researcher – Leukemia (Josep Carreras Leukaemia Research Institute) Director – Blood Research Institute (Versiti) Postdoctoral Positions – Leukemia (Temple University School of Medicine) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Cord Blood News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|